Baylor College of Medicine: Mutated Blood Cells Define Clinical Risks in Langerhans Cell Histiocytosis, Paving the Way for Better Diagnosis and Treatment
April 02, 2025
April 02, 2025
HOUSTON, Texas, April 2 -- The Baylor College of Medicine issued the following news:
* * *
Mutated blood cells define clinical risks in Langerhans cell histiocytosis, paving the way for better diagnosis and treatment
A nationwide team led by researchers at Baylor College of Medicine, Texas Children's Hospital and UPMC Children's Hospital of Pittsburgh has proposed a major revision to how Langerhans cell histiocytosis (LCH) is diagnosed and treated . . .
* * *
Mutated blood cells define clinical risks in Langerhans cell histiocytosis, paving the way for better diagnosis and treatment
A nationwide team led by researchers at Baylor College of Medicine, Texas Children's Hospital and UPMC Children's Hospital of Pittsburgh has proposed a major revision to how Langerhans cell histiocytosis (LCH) is diagnosed and treated . . .